Clinical Study Results
Research Sponsor: MedImmune
Drug Studied: Durvalumab and MEDI9090, a mixture of durvalumab
and tremelimumab
Study Title: A study to learn about the safety of durvalumab and
MEDI9090 in participants with advanced solid tumors
Thank you!
Thank you for taking part in the clinical study for the study drugs durvalumab
and MEDI9090. MEDI9090 is a combination of the study drugs durvalumab and
tremelimumab.
MedImmune sponsored this study and believes it is important to share the results.
An independent non-profit organization called CISCRP helped prepare this
summary of the study results for you.
If you participated in the study and have questions about the results, please speak
with the study doctor or staff at your study site.
Who took part in the study?
The researchers asked for the help of people with advanced solid tumors. The
participants in this study were 28 to 78 years old when they joined.
The study included 42 participants in Japan and the United States.
1